List of Excipients in Branded Drug DAYVIGO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eisai Inc	DAYVIGO	lemborexant	62856-405	FERRIC OXIDE YELLOW	2035-10-21
Eisai Inc	DAYVIGO	lemborexant	62856-405	HYDROXYPROPYL CELLULOSE	2035-10-21
Eisai Inc	DAYVIGO	lemborexant	62856-405	HYPROMELLOSE 2910	2035-10-21
Eisai Inc	DAYVIGO	lemborexant	62856-405	LACTOSE MONOHYDRATE	2035-10-21
Eisai Inc	DAYVIGO	lemborexant	62856-405	LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE	2035-10-21
Eisai Inc	DAYVIGO	lemborexant	62856-405	MAGNESIUM STEARATE	2035-10-21

DAYVIGO Excipient Strategy and Commercial Opportunities for Lemborexant

Last updated: August 4, 2026

DAYVIGO, the brand name for lemborexant, is an immediate-release, film-coated tablet for adult insomnia. Its commercial opportunity is concentrated in generic tablets, differentiated oral dosage forms, global reformulation, and excipient-led manufacturing improvements. The reference product uses a conventional tablet platform, which lowers technical barriers for an ANDA applicant but leaves room for improved dissolution, lower pill burden, pediatric or geriatric administration, and lifecycle products under a 505(b)(2) pathway.

What is DAYVIGO and how is it formulated?

DAYVIGO contains lemborexant, a dual orexin receptor antagonist that inhibits orexin OX1R and OX2R signaling. The U.S. product is supplied in 5 mg and 10 mg immediate-release tablets. The recommended starting dose is 5 mg, with an increase to 10 mg when clinically appropriate. Patients should take the drug immediately before bedtime and have at least seven hours available for sleep.[1]

The FDA-approved tablet has a relatively conventional excipient profile:

Formulation element	DAYVIGO approach	Commercial significance
Active ingredient	Lemborexant, 5 mg or 10 mg	Low-dose formulation requires content-uniformity control
Dosage form	Immediate-release film-coated tablet	Suitable for conventional generic development
Core excipients	Lactose monohydrate, mannitol, crospovidone, povidone, magnesium stearate and talc	Supports dilution, binding, disintegration and lubrication
Coating	Film coating with standard coating materials and colorants	Enables strength differentiation and swallowability
Release profile	Immediate release	Reduces modified-release development complexity
Administration	Oral, at bedtime	Excipient selection must preserve rapid and reproducible dissolution

The active ingredient is administered at a low dose relative to the tablet mass. That creates formulation priorities around blend uniformity, segregation control, lubrication sensitivity and dissolution reproducibility.

What excipients are used in DAYVIGO tablets?

The core DAYVIGO formulation combines a diluent system with conventional wet- or dry-granulation-compatible processing aids. Lactose monohydrate and mannitol provide tablet mass and compression characteristics. Povidone functions as a binder, while crospovidone supports rapid disintegration. Magnesium stearate provides lubrication, and talc can support processing and coating performance.[1]

The formulation creates several development considerations:

Lactose and mannitol

The combination gives a formulation developer multiple options for balancing compactability, mouthfeel and dissolution. Mannitol can improve tablet hardness and reduce the perception of a chalky tablet. Lactose can improve compressibility but may create supply, compatibility and patient-labeling considerations.

A generic manufacturer could replace part or all of the lactose with microcrystalline cellulose, spray-dried lactose, dibasic calcium phosphate or a co-processed excipient. Each substitution would affect tablet density, hardness, friability, disintegration and dissolution.

Crospovidone

Crospovidone is a strong candidate for optimization because disintegrant grade and concentration can materially affect water uptake and tablet breakup. Excessive compression force or over-lubrication can reduce the benefit of the disintegrant.

Povidone and magnesium stearate

Povidone level and molecular weight influence granule strength and dissolution. Magnesium stearate concentration and blending time require control because over-lubrication can create hydrophobic surfaces, slow disintegration and alter dissolution.

Film coating

The low-dose strengths require clear strength identification. A generic product can use a different color system if it complies with FDA inactive-ingredient requirements and labeling rules. A coating modification can also improve mechanical protection, reduce friability and improve swallowability without changing the immediate-release design.

What excipient strategy is most attractive for DAYVIGO generics?

The strongest generic strategy is a Q1/Q2-conscious immediate-release tablet that maintains the reference product’s dissolution profile while reducing manufacturing cost or supply-chain dependence.

Strategy 1: Reference-like conventional tablet

This is the lowest-risk route. The manufacturer would use the same or functionally similar excipient classes, match the reference strength and tablet performance, and develop a standard ANDA.

Key development targets include:

• Uniform distribution of lemborexant at 5 mg and 10 mg.
• Rapid disintegration across physiological pH conditions.
• Comparable dissolution under FDA-relevant media.
• Robustness against magnesium stearate over-lubrication.
• Stable assay and impurity profile under accelerated storage.
• Consistent film-coating weight and color differentiation.

This route is likely to face the lowest regulatory and commercial risk but also the greatest price competition.

Strategy 2: Lactose-free or low-lactose formulation

A lactose-free formulation could address patients with lactose intolerance, excipient avoidance preferences or procurement requirements. Mannitol, microcrystalline cellulose or a co-processed filler could replace lactose.

The commercial value is likely to be incremental rather than transformational. Most tablet products do not receive strong market differentiation solely from lactose removal. The opportunity improves if the formulation also provides better flow, lower tablet weight or a more reliable global supply chain.

Strategy 3: Direct-compression platform

A direct-compression formulation could reduce manufacturing steps and eliminate granulation equipment. The main technical challenge is achieving acceptable content uniformity at a low active load while preserving tablet strength and dissolution.

A co-processed filler-binder, low-substitution hydroxypropyl cellulose or a specialized mannitol-cellulose system could support direct compression. Process development would need to control segregation caused by differences in particle size, density and morphology between lemborexant and the excipients.

Strategy 4: Fast-disintegrating tablet

A faster-disintegrating tablet could improve administration for older adults and patients with difficulty swallowing. A conventional fast-disintegrating tablet may be developed as an ANDA product if it remains pharmaceutically equivalent and satisfies applicable bioequivalence requirements. An orally disintegrating tablet with a distinct dosage form or performance profile could instead require a 505(b)(2) strategy.

The formulation would likely use:

• Highly porous mannitol or a co-processed filler.
• Crospovidone or low-substituted hydroxypropyl cellulose.
• Low lubricant levels.
• Taste-masking technology if disintegration occurs in the mouth.
• A moisture-protective package.

Taste masking is a meaningful barrier because lemborexant’s sensory profile and dose uniformity must be controlled without slowing dissolution.

What DAYVIGO formulation patents and regulatory barriers matter?

DAYVIGO is a small-molecule product, so biosimilar regulation does not apply. A competing product would generally use an ANDA for a pharmaceutically equivalent generic or a 505(b)(2) application for a materially different formulation, route, dosage form or clinical use.

ANDA pathway

An ANDA applicant must address the reference listed drug’s patents and exclusivity and demonstrate pharmaceutical equivalence and bioequivalence. Excipient changes are common in ANDA products, but they cannot compromise safety, quality, performance or bioequivalence.

For an immediate-release tablet, the principal technical barriers are usually:

• Drug loading and content uniformity.
• Dissolution similarity.
• Solid-state control.
• Food-effect sensitivity.
• Stability of a low-dose active.
• Manufacturing scale-up.

505(b)(2) pathway

A 505(b)(2) product could pursue a differentiated dosage form such as:

• Orally disintegrating tablet.
• Chewable tablet.
• Sprinkle formulation.
• Oral liquid or suspension.
• Alternative strength or administration system.
• Formulation designed for geriatric or institutional use.

This route can create greater commercial differentiation but may require additional clinical, pharmacokinetic or safety work. A new formulation could also trigger patent claims directed to dosage forms, excipient combinations, particle size, solid-state forms or methods of treating insomnia.

Orange Book and patent review

The FDA Orange Book is the controlling source for current U.S. patent and exclusivity listings for DAYVIGO. Applicants must review the active ingredient, formulation, method-of-use and other listed patent categories before filing an ANDA.[2]

A commercial diligence review should distinguish:

IP category	Relevance to excipient strategy
Compound patents	Can block generic lemborexant regardless of excipient selection
Composition or formulation patents	May cover tablet architecture, excipient combinations or release characteristics
Polymorph and crystalline-form patents	Can affect active-ingredient sourcing and solid-state selection
Method-of-use patents	May require Paragraph IV or Section viii treatment depending on claim scope
Manufacturing patents	Can affect API production, particle size, purification or formulation inputs
Pediatric or regulatory exclusivity	Can delay or restrict approval even if formulation patents are avoided

An excipient redesign does not avoid a valid compound patent. It is most valuable when the remaining barriers are formulation or process claims.

When does DAYVIGO lose exclusivity?

DAYVIGO’s commercial exclusivity depends on the interaction of FDA regulatory exclusivity, Orange Book-listed patents, pediatric extensions and any litigation or settlement agreements. The FDA label establishes the approval date and approved indication, but the precise generic-entry date must be determined from the current Orange Book and applicable patent certifications.[1,2]

U.S. exclusivity considerations

The relevant categories are:

• New chemical entity exclusivity, if applicable to the original approval.
• Orange Book-listed patents.
• Pediatric exclusivity, if granted.
• Any 30-month stay resulting from timely patent litigation.
• Any authorized generic or settlement provisions.
• State and international patent rights unrelated to the U.S. ANDA timetable.

A manufacturer should not treat the first apparent patent expiration as the guaranteed launch date. Patent-term adjustment, patent-term extension, pediatric exclusivity, litigation outcomes and settlement terms can change the effective market-entry date.

Generic launch scenarios

Scenario	Commercial effect
No ANDA challenge before key patent expiry	Entry begins after applicable patent barriers expire
Paragraph IV challenge with no litigation	Potential approval after FDA review and statutory timing
Paragraph IV challenge followed by litigation	Potential 30-month stay, subject to court and FDA events
First successful Paragraph IV applicant	Possible 180-day generic exclusivity
Formulation-only 505(b)(2) launch	Potential entry through a differentiated product, subject to patents and clinical requirements
Authorized generic launch	Greater price pressure and reduced value of first generic entry

What commercial opportunities exist beyond a standard generic tablet?

The best opportunities are products that solve administration, adherence or supply-chain problems rather than merely reproduce the reference tablet.

Geriatric and dysphagia-focused products

Insomnia prevalence increases with age, while swallowing difficulty and polypharmacy complicate tablet use. A fast-disintegrating or small-format tablet could target assisted-living, long-term-care and home-care settings.

The formulation must preserve dose accuracy and avoid rapid exposure changes that could affect next-day impairment or adverse effects. Lemborexant labeling includes warnings concerning central nervous system depression, complex sleep behaviors and next-day impairment, making pharmacokinetic comparability important.[1]

Institutional packaging

Unit-dose blister packaging, calendar packs and adherence-oriented packaging can create commercial value without changing the active formulation. Packaging may improve control over bedtime administration and reduce medication errors.

A moisture-barrier blister could also support an ODT or porous tablet, particularly where mannitol-rich formulations have increased moisture sensitivity.

Global excipient localization

A manufacturer can reduce cost and supply risk by qualifying regional sources for lactose, mannitol, crospovidone, povidone and coating materials. The main constraints are excipient grade consistency, impurity control, microbiological quality and regulatory documentation.

A global formulation should account for:

• FDA inactive-ingredient requirements.
• European excipient-labeling requirements.
• Japanese PMDA expectations.
• Local colorant restrictions.
• Nitrosamine and elemental-impurity risk assessments.
• Regional packaging and stability conditions.

Product-line extensions

A manufacturer with commercial access to insomnia products could use DAYVIGO as part of a broader portfolio that includes generic hypnotics, sleep-disorder products and geriatric formulations. The value increases when the same manufacturing platform supports several low-dose products.

How does DAYVIGO compare with other insomnia drugs?

DAYVIGO competes with orexin antagonists and older sedative-hypnotics. Its excipient opportunity differs by product class.

Product class	Representative products	Formulation opportunity
Dual orexin antagonist	Lemborexant, suvorexant	Immediate-release generic, ODT, institutional packaging
Selective orexin antagonist	Daridorexant	Similar oral-solid opportunities, with separate patent analysis
Z-drugs	Zolpidem, eszopiclone, zaleplon	Mature generic markets with stronger price pressure
Melatonin-related products	Ramelteon and others	Alternative formulations and lower-sedation positioning
Benzodiazepines	Several generic products	Established supply base but greater safety and controlled-substance considerations

DAYVIGO’s main technical advantage for a generic developer is the simplicity of an immediate-release tablet. Its main commercial challenge is the need to compete against established low-cost insomnia generics and other branded orexin antagonists.

How strong is the excipient and formulation opportunity for DAYVIGO?

The formulation opportunity is moderate for a conventional generic and stronger for differentiated oral delivery.

Opportunity	Technical difficulty	Commercial differentiation
Reference-like tablet	Low to moderate	Low
Lactose-free tablet	Moderate	Low to moderate
Direct-compression tablet	Moderate	Moderate through cost reduction
Fast-disintegrating tablet	Moderate to high	Moderate to high
ODT with taste masking	High	High
Oral liquid or suspension	High	High, but limited target population
Sprinkle formulation	High	Moderate to high
New modified-release system	High	Uncertain and clinically demanding

The most defensible development plan is usually a two-track program: a conventional immediate-release tablet for near-term ANDA economics and a differentiated fast-disintegrating or geriatric-friendly product for longer-term margin protection.

What manufacturing and IP barriers affect commercial entry?

Manufacturing barriers are manageable but should be addressed early. The most important controls are API particle-size distribution, blend uniformity, lubrication time, compression force, coating uniformity and dissolution after scale-up.

Potential IP barriers include:

• Lemborexant compound protection.
• Crystalline or polymorphic forms.
• Particle-size specifications.
• Formulation claims.
• Tablet coating or strength-identification claims.
• Treatment claims for insomnia subpopulations.
• Manufacturing-process claims.

A non-infringing formulation should be supported by claim mapping before process lock. Substituting an excipient is not sufficient if the relevant patent claim covers the active ingredient, a solid-state form or a broad composition.

What is the investment case for DAYVIGO excipient development?

The commercial case depends on entry timing and product positioning.

A conventional generic requires limited formulation innovation but faces rapid price erosion. An ODT, geriatric tablet or institutional product can support higher margins but requires more development, stability and regulatory work. The strongest return profile is likely to come from a product that combines:

1. A low-cost immediate-release manufacturing process.
2. A robust, globally sourced excipient system.
3. A differentiated administration option.
4. A packaging design suited to adherence and institutional dispensing.
5. A clear patent and regulatory pathway.

Revenue exposure should be modeled against three variables: the effective generic-entry date, the number of approved ANDA competitors and the share captured by differentiated formulations. Eisai’s annual reports and product disclosures provide the relevant branded-sales baseline for DAYVIGO and should be combined with IQVIA or equivalent prescription data for market sizing.[3]

Key Takeaways

• DAYVIGO is a 5 mg and 10 mg immediate-release lemborexant film-coated tablet.
• Its excipient platform is conventional and technically accessible to generic developers.
• The main formulation challenges are low-dose content uniformity, dissolution control, lubrication sensitivity and stability.
• Lactose-free, direct-compression and mannitol-based alternatives are feasible but require comparative performance testing.
• Fast-disintegrating, ODT and geriatric-focused products offer more commercial differentiation than a standard generic tablet.
• DAYVIGO has no biosimilar pathway because lemborexant is a small molecule.
• Orange Book patents, regulatory exclusivity, Paragraph IV filings and litigation determine the U.S. entry timetable.
• Excipient substitution cannot avoid compound or broad active-ingredient patent claims.
• The strongest commercial strategy is a conventional ANDA product paired with a differentiated oral-delivery lifecycle product.

FAQs

Can a generic DAYVIGO tablet use different excipients?

Yes. An ANDA applicant may use different inactive ingredients if the product remains pharmaceutically equivalent, meets safety and quality requirements, and demonstrates bioequivalence. The formulation must also comply with FDA inactive-ingredient and labeling requirements.

Is an orally disintegrating DAYVIGO product commercially attractive?

Yes, particularly for older adults and patients with dysphagia. The product would face higher technical requirements for taste masking, moisture protection, content uniformity and pharmacokinetic comparability.

Does DAYVIGO have biosimilar competition?

No. Lemborexant is a chemically synthesized small molecule. Competition would arise through generic ANDAs or potentially 505(b)(2) formulations, not biosimilar applications.

Can an excipient change avoid DAYVIGO patent infringement?

Only in limited circumstances. An excipient redesign may avoid a narrow formulation claim, but it will not avoid a valid compound, polymorph, method-of-use or broad composition patent.

Which excipients are most important for DAYVIGO generic development?

The highest-impact excipients are the diluent system, crospovidone, povidone and magnesium stearate. Their grade, concentration and processing conditions can materially affect content uniformity, tablet strength, disintegration and dissolution.

References

1. U.S. Food and Drug Administration. (2024). DAYVIGO (lemborexant) tablets, for oral use: Prescribing information. Eisai Inc.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. Eisai Co., Ltd. (2024). Annual report and financial results materials. https://www.eisai.com/ir/ truncated (no)